Zoledronic acid monotherapy improves osteoarticular involvement in SAPHO syndrome
Authors:
- 2 September 2020
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 49 (5) , 419-421
Abstract
(2020). Zoledronic acid monotherapy improves osteoarticular involvement in SAPHO syndrome. Scandinavian Journal of Rheumatology. Ahead of Print.Keywords
This publication has 8 references indexed in Scilit:
- SAPHO: Treatment options including bisphosphonatesSeminars in Arthritis and Rheumatism, 2016
- SAPHO Syndrome: Current Developments and Approaches to Clinical TreatmentCurrent Rheumatology Reports, 2016
- Zoledronic Acid Effective as Rescue Treatment for Ankylosing Spondylitis Refractory to TNF InhibitionAnnals of Pharmacotherapy, 2015
- Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: Results from a nationwide patient surveySeminars in Arthritis and Rheumatism, 2014
- Intra-Articular Glucocorticosteroid Injection into Sternocostoclavicular Joints in Patients with SAPHO SyndromeSeminars in Arthritis and Rheumatism, 2012
- Successful treatment of SAPHO syndrome with zoledronic acidArthritis & Rheumatism, 2004
- Bone scintigraphy using Tc‐99m DPD and F18‐FDG in a patient with SAPHO syndromeScandinavian Journal of Rheumatology, 2003
- Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studiesSeminars in Oncology, 2001